Home
Live
News
Create
Screeners
Insights
Sanjivani Paranteral
211.
75
+1.55
(+0.74%)
Market Cap
₹258.20 Cr
PE Ratio
32.08
Industry
Healthcare
Buy
Sell
Company Performance:
1D
+0.74%
1M
-8.29%
6M
-15.65%
1Y
-25.64%
5Y
+2,181.79%
View Company Insights
Latest news about Sanjivani Paranteral
Sanjivani Paranteral Appoints Pharma Veteran Basant Shrivastava as Independent Director
Sep 11, 2025
Sanjivani Paranteral Limited has appointed Mr. Basant Shrivastava as an Additional Director in the Independent Category, effective September 11, 2025. Shrivastava, with 40 years of pharmaceutical industry experience, joins for a five-year term as a Non-Executive Independent Director. His appointment, subject to shareholder approval, was recommended by the Nomination and Remuneration Committee. Shrivastava's background includes leadership roles at Johnson & Johnson, Nelson Chemical, and current positions at Vita Pharma Agencies and Joint Force Pharma Ltd. He is known for his sales and marketing expertise in the pharmaceutical sector.
Sanjivani Parenteral Launches Commercial Production at New IV Fluid Plant in Pune
Sep 08, 2025
Sanjivani Parenteral Reports 8.9% Revenue Growth in Q1, Pune Facility Set for Commercial Production
Aug 18, 2025
Sanjivani Paranteral Reports 8.9% Revenue Growth in Q1 FY26, Driven by Strong Injectables Performance
Aug 12, 2025
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/Block Deals
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation